CN111665350A - Nanometer biological monitor for blood cruising - Google Patents
Nanometer biological monitor for blood cruising Download PDFInfo
- Publication number
- CN111665350A CN111665350A CN202010550977.6A CN202010550977A CN111665350A CN 111665350 A CN111665350 A CN 111665350A CN 202010550977 A CN202010550977 A CN 202010550977A CN 111665350 A CN111665350 A CN 111665350A
- Authority
- CN
- China
- Prior art keywords
- component
- cancer
- blood
- monitoring
- cruising
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 238000012544 monitoring process Methods 0.000 claims abstract description 38
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 239000000523 sample Substances 0.000 claims abstract description 6
- 238000003745 diagnosis Methods 0.000 claims abstract description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 32
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 26
- 210000002966 serum Anatomy 0.000 claims description 16
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 13
- 102100023123 Mucin-16 Human genes 0.000 claims description 13
- 238000004891 communication Methods 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 2
- 210000000080 chela (arthropods) Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 18
- 108091023037 Aptamer Proteins 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- -1 alkyl azide Chemical class 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 210000003050 axon Anatomy 0.000 description 7
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 235000010378 sodium ascorbate Nutrition 0.000 description 7
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 7
- 229960005055 sodium ascorbate Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000002086 nanomaterial Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005543 nano-size silicon particle Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a nano biological monitor for blood cruising, which comprises a cruising component, a monitoring component, a sensing component and a framework component. The whole detector is driven by the molecular motor to cruise in blood, biochemical parameters in the blood are monitored in real time, wherein the nano biological monitor for emergently detecting blood antigens has higher response frequency and extremely fast response time, and different aptamers used for different cancer antigens are different and do not influence each other, so that the nano biological monitor has specificity. The monitoring probe is transmitted to the AR equipment host unit through an electric signal, if the parameters exceed the matching range, the AR display unit is activated, and the information of each parameter is displayed on the AR equipment. The invention adopts AR technology to carry out remote monitoring on human blood, is timely and intuitive, is convenient for popping up image information to a doctor in real time, and the doctor gives a warning to make diagnosis according to the image information and contacts a patient to treat the patient in time.
Description
Technical Field
The invention relates to the technical field of nano biosensors and AR display, in particular to a nano biological monitor for blood cruising.
Background
90% of early cancers have no obvious symptoms, 80% of cancer patients in China belong to middle and late stages when diagnosed, the survival rate of the cancer is extremely low after 5 years, the general survival period of the late lung cancer is only 1 year, and the survival period of jaundice and ascites at the late liver cancer is 1 to 3 months. The mortality rate of the gastric cancer is second to that of the gastric cancer of lung cancer and liver cancer, if the lesion is found early, the five-year survival rate after operation can reach 85% to 95%, but the lesion only accounts for the first one of gastric cancer patients in China, which means that many patients miss the optimal treatment period when finding the lesion. Therefore, early diagnosis, early treatment and timely disease control are the key to cancer treatment. The tumor marker is an important biochemical substance for reflecting the existence and growth of tumors, and plays an important role in the diagnosis, curative effect observation and relapse monitoring of cancers.
The conventional biological monitoring of tumor markers has the result of being divided into positive and negative. A positive result indicates that the subject may have a tumor, and a negative result indicates that the subject may not have a tumor. However, the examination result can only obtain the result of whether the tumor exists in the detected person, and there is no way to know the tumor position of the detected person. Moreover, the false positive rate and the false negative rate are relatively high, so that at present, in clinic, many patients with cancer positive results are monitored, and many clinical examinations are continuously carried out, and the focus of the tumor can not be found, so that the traditional tumor monitoring method is really found early, but cannot realize early diagnosis and early treatment.
The nanometer biological sensing machine is one nanometer biological machine for fast detection of nucleic acid and protein, and consists of inorganic nanometer structure of several dimensions and material and several kinds of biological molecules, and can realize the integration of the functions of identifying, trapping, signal transduction, cascade amplification, etc. and thus realize biological detection in one single system. Conventional nano biosensors are often just a composite of one kind of nanomaterial and one kind of biomolecule (recognition element), and thus integration of functions is difficult.
The AR technology is augmented reality technology, the goal of the technology is to overlay a virtual scene in a real scene on a screen and perform interaction, so that not only is real world information displayed, but also virtual information is displayed simultaneously, and the two kinds of information are mutually supplemented and overlaid. And receiving and reminding information in real time.
Disclosure of Invention
The invention aims to solve the problem of the untrustworthiness of the traditional method for detecting the blood tumor marker, and provides a nano biological monitor for blood cruising and an AR type emergency display method thereof.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a nanobiodetector for blood navigation, comprising: the device comprises a framework component, a cruise component, a monitoring component and a sensing component.
The cruise component is a three-strand DNA molecular motor. The molecular machine is not only a structural material but also a self-acting force, and is formed into a pincer shape by hybridization of the three oligonucleotide strands A, B, C. Switching is effected by means of a further auxiliary DNA strand, in which one oligonucleotide strand F is hybridized to the free end of strand B, C, the pincer-like molecule is closed, and subsequently, the complementary strand of F is passed
The pincer-like molecules are opened to circulate, thereby achieving the effect of cruise motion.
The monitoring component utilizes the nano-structure surface of the framework component to control the accurate assembly of various biomolecules in different areas of the nano-structure surface, and is assembled to have a structure with a plurality of functional areas. Each functional area of the functional area comprises: a recognition capture region, a signal conduction region and a cascade amplification region. Wherein each recognition capture region can specifically capture corresponding tumor-specific protein molecules including serum alpha-fetoprotein (AFP), cancer antigen 242(CA242), cancer antigen 125(CA125), cancer antigen 153(CA153), cancer antigen 724(CA724) after assembly of the biological recognition element; the signal transduction area can convert the biological recognition process into light or electric signals through the photoelectric effect of the nano-wire/nano-tube, and can realize the simultaneous output of various signals so as to improve the signal specificity; the cascade amplification part can realize signal multiplication through a plurality of enzyme reactions on the surface of the nano structure, and the detection sensitivity is improved. And transmits the resulting optical or electrical signal to the sensing component.
The sensing component is a wireless sensing chip. It includes acquisition unit and communication unit. The collection unit is used for contacting with the monitoring component, collecting signals of the probes through signal conduction, converting the signals into biochemical parameters, and collecting and transmitting the parameters to the AR equipment through the communication unit.
The framework component is mesoporous nano silicon dioxide. For support and protection of other components. It exhibits uniform spheres, wherein the mesoporous silica has a particle size in the range of 30 to 90nm, preferably in the range of 50 to 80 nm.
The nano biological monitor has higher response frequency and extremely fast response time in emergency detection of blood antigens, and aptamers used by different cancer antigens are different and do not influence each other, so that the nano biological monitor has specificity. It is 31min in terms of response time-1。
A component for an AR emergency display, comprising: a host unit and a display unit of the AR device.
And the host unit receives signals transmitted by the communication unit in the sensing part through wifi and processes all parameters. Wherein, the processing principle is as follows: serum alpha-fetoprotein (AFP) exceeds a threshold value, which indicates the occurrence of primary liver cancer; cancer antigen 242(CA242) exceeds a threshold, indicating the possible occurrence of pancreatic and gallbladder cancer; cancer antigen 125(CA125) exceeds a threshold, indicating the likely occurrence of ovarian cancer; cancer antigen 153(CA153) exceeds a threshold, indicating the likely occurrence of breast cancer; cancer antigen 724(CA724) exceeds a threshold, indicating the possible occurrence of gastric cancer. The host unit integrates the signal information of the cruising nanometer biological monitor in the blood of each patient, the personal information of the patient in the database thereof and the matched biochemical index range of each parameter, and if any one of the parameters exceeds the matched range after being processed, the display unit is immediately activated. If all the parameters are in the matching range, the display unit is silent.
The display unit projects the received parameter information, chart, image and other information. The system comprises personal information of a patient, previous cases, a diseased part, biochemical indexes of various parameters received in real time, and a real-time image of the position of a focus where a nano biological monitor is located, so as to give a warning to a doctor. At this time, the display unit of the AR appears immediately in front of the doctor in the form of a display screen, regardless of the time and place where the doctor is, and regardless of what matters are being done.
The invention relates to a nanometer biological monitor for blood cruising and an AR type emergency display method thereof, biochemical indexes in blood are monitored in real time through cruising and transmitted to an AR component through signals, if an emergency occurs, biochemical information of a patient is combined with an image of a focus part and personal information of the focus part is integrated, and the biochemical information is immediately and accurately displayed to a doctor.
Compared with the prior art, the invention has reasonable design and large development space, and the technology is widely applied, can realize early diagnosis and early treatment, control the state of an illness in time, reduce the pain of patients in treatment places such as chemotherapy after illness, reduce the medical treatment cost to a great extent for families and countries, and improve the health and life index of the nation.
Drawings
FIG. 1 is a skeletal assembly of a nanobody detector according to the present invention;
FIG. 2 is a schematic flow chart of a specific embodiment of the present invention.
Detailed Description
With the development of nanotechnology, it is also beginning to be used in medicine. The nanometer level organism can move freely in blood vessel and can be transported to various parts of organism for monitoring and diagnosing diseases, and based on the function of the ultramicron, the functional molecular device capable of operating in nanometer space is designed and manufactured for designing prototype based on the biological principle of molecular level. It has the function of recognizing protein, produces specific effect on specific target cell and is used mainly in early diagnosis of hard-to-cure diseases.
The following is a detailed description of the method of the present invention, which is carried out on the premise of the technical solution of the present invention, and detailed embodiments and specific procedures are given, but the scope of the present invention is not limited to the following method.
As shown in fig. 1, the skeleton member of the present embodiment is a mesoporous silica nanomaterial. The monitoring component is embedded on the surface of the monitoring component, the sensing component is wrapped on the core of the monitoring component, and the cruising component is connected on the surface of the monitoring component. It exhibits uniform spheres, wherein the mesoporous silica has a particle size in the range of 30 to 90nm, preferably in the range of 50 to 80 nm.
As shown in fig. 2, the nano biochemical detector module in the present embodiment includes: the device comprises a framework component, a cruise component, a monitoring component and a sensing component. Wherein, the skeleton part is as system support, and the part that cruises is as the motion unit, cruises. The monitoring component conducts the biochemical signals to the sensing component through the combination with the specific protein, and transmits the signals to the AR display component through wifi signals.
The cruise component is a three-strand DNA molecular motor.
The monitoring component is used for monitoring probe regions of serum alpha-fetoprotein (AFP), cancer antigen 242(CA242), cancer antigen 125(CA125), cancer antigen 153(CA153) and cancer antigen 724(CA 724).
The sensing component is a wireless sensing chip. It includes acquisition unit and communication unit.
As shown in fig. 2, the AR-type emergency display module in the present embodiment includes: a host unit and a display unit of the AR device.
And the host unit receives signals transmitted by the communication unit in the sensing part through wifi and processes all parameters. Wherein, the processing principle is as follows: serum alpha-fetoprotein (AFP) exceeds a threshold value, which indicates the occurrence of primary liver cancer; cancer antigen 242(CA242) exceeds a threshold, indicating the possible occurrence of pancreatic and gallbladder cancer; cancer antigen 125(CA125) exceeds a threshold, indicating the likely occurrence of ovarian cancer; cancer antigen 153(CA153) exceeds a threshold, indicating the likely occurrence of breast cancer; cancer antigen 724(CA724) exceeds a threshold, indicating the possible occurrence of gastric cancer. The host unit integrates the signal information of the cruising nanometer biological monitor in the blood of each patient, personal information and biochemical indexes of all parameters, and if any condition exists after the parameters are processed, the signals are immediately popped up on the display unit. If all the parameters are in the matching range, the display unit is silent.
The display unit projects the received parameter information, chart, image and other information.
The method specifically comprises the following steps:
A. the cruising component of the molecular motor drives the whole system to freely shuttle in blood. During movement, probes in all areas of the monitoring part act with specific tumor marker proteins.
B. After the monitoring component captures the corresponding tumor specific protein, the monitoring component transmits an electric signal to the sensing component through the action of signal conduction and cascade amplification, and releases the captured protein.
C. The sensing part receives the signal of the monitoring part and transmits the signal to the AR equipment host unit of the AR type emergency display module through wifi, the host unit judges the obtained biochemical parameters according to the received signal, if the biochemical parameters are judged to be healthy in a matching range, the nanometer biochemical detector continues to cruise and transmit the signal.
D. If the signal received by the AR host is not in the matching range, the signal is judged to be unhealthy, the host unit integrates the signal information, the personal information and the biochemical indexes of all parameters of the cruise nanometer biological monitor in the blood of each patient, and immediately and accurately displays the signal information, the personal information and the biochemical indexes of all parameters to a doctor, wherein the information comprises the name, the contact way, the original diseased condition or the carried genetic disease of the patient, the condition of the latest physical examination, the emergency biochemical parameters, the standard area biochemical parameters, the affiliated diseased condition and the like of the patient, and is popped in front of the doctor in the form of images and tables.
E. The doctor can timely contact the patient for further monitoring or treatment according to the judgment of the biochemical index information.
The present invention will be described in detail below by way of examples.
Example 1
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (100 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (200mM) in acetonitrile, 1 μ L of 20 μ M sodium ascorbate, 0.5 μ L of 20 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, finally adding 2 μ L of 100mM EDTA solution. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Example 2
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (80 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (160mM) in acetonitrile, 1 μ L of 16 μ M sodium ascorbate, 0.5 μ L of 16 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, and finally 2 μ L of 100mM EDTA solution was added. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digital converter 1440AA/D (axon instruments).
Example 3
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (200 μ M), 1.2 μ L deionized water, 2 μ L ferrocenyl alkyl azide in acetonitrile (400mM), 1 μ L sodium ascorbate at 40 μ M, 0.5 μ L40 μ M copper nitrate, added to 2 μ L100 mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, finally adding EDTA 2 μ L100 mM solution. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Example 4
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (300 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (600mM) in acetonitrile, 1 μ L of 60 μ M sodium ascorbate, 0.5 μ L of 60 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, and finally 2 μ L of 100mM ethylenediaminetetraacetic acid solution was added. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Example 5
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (40 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (80mM) in acetonitrile, 1 μ L of 8 μ M sodium ascorbate, 0.5 μ L of 8 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, and finally 2 μ L of 100mM ethylenediaminetetraacetic acid solution was added. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Example 6
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (20 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (40mM) in acetonitrile, 1 μ L of 4 μ M sodium ascorbate, 0.5 μ L of 4 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, and finally 2 μ L of 100mM EDTA solution was added. The DNA product was passed through a spin column (MicroBio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Example 7
This example illustrates the ability to detect blood antigens for emergency in a nanobiotte monitor.
(1) Preparation of nanopore for detecting interaction between molecular aptamer and host-guest
3.3 μ L of alkynyl end chain containing DNA (10 μ M), 1.2 μ L deionized water, 2 μ L of ferrocenyl alkyl azide (20mM) in acetonitrile, 1 μ L of 2 μ M sodium ascorbate, 0.5 μ L of 2 μ M copper nitrate, added to 2 μ L of 100mM buffer, final concentration of 10ul, incubated at room temperature for 2 hours, and finally 2 μ L of 100mM EDTA solution was added. The DNA product was passed through a spin column (Micro Bio-spin P6 column). Next, 10 μ L of 5mM CB solvent was added to the above solution, and after incubation for 2 hours, the final nanopore monitoring member was obtained, and the thioacetic bond on the nanopore was connected to the thiol of the mesoporous silica of the backbone member under stirring.
(2) Ability to detect blood antigens in emergency and emergency display ability
The DNA nanopore is incubated with serum alpha-fetoprotein (AFP) at a final concentration of 5. mu.M, at 37 ℃ in which a buffer of 100mM sodium chloride, 5mM potassium chloride, 10mM hydrochloric acid, pH7.4 is added to the final solution, so that the final solution volume is 50. mu.L. The time to emergency response was then determined by single channel recording experiments using a digitizer 1440A A/D (axon instruments).
Comparative example 1
This comparative example serves to illustrate the ability to detect blood antigens in an emergency in a reference nanobiotom.
The time to emergency response was measured as in example 1, except that 5. mu.M of serum alpha-fetoprotein (AFP) was 5. mu.M of cancer antigen 242(CA 242).
Comparative example 2
This comparative example serves to illustrate the ability to detect blood antigens in an emergency in a reference nanobiotom.
The time to emergency response was measured as in example 1, except that 5. mu.M of serum alpha-fetoprotein (AFP) was 5. mu.M of cancer antigen 125(CA 125).
Comparative example 3
This comparative example serves to illustrate the ability to detect blood antigens in an emergency in a reference nanobiotom.
The time to emergency response was measured as in example 1, except that 5. mu.M of serum alpha-fetoprotein (AFP) was 5. mu.M of cancer antigen 153(CA 153).
TABLE 1
As can be seen from table 1 above, in the ability of detecting blood antigens in a nanobiotte monitor for emergency detection, example 1 has a higher response frequency and a very fast response time, which is the most preferable condition of the present invention. In addition, other cancer antigens are most preferred by using different molecular aptamers and using the same preparation method. The aptamers used for different cancer antigens are different and do not influence each other. The detected response time is also one of the important factors that determine the rate of the final AR display. And under the optimal conditions of the invention, for example, the signal transmission mode of the detector and the emergency component, the performance of the nano biosensor can be further improved in combination with the new generation nano drug delivery and the like.
It is to be understood that the above description is only exemplary of the present invention and is not intended to limit the scope of the present invention, and that the appended claims are intended to cover all such modifications and changes as fall within the true spirit and scope of the invention.
Claims (2)
1. A nano-bio monitor, comprising:
the cruising component is used for providing power for the whole body and continuously cruising in blood; the cruising component is a three-strand DNA molecular motor; the molecular machine not only is a structural material, but also has the function of providing power by itself, and the three oligonucleotide chains A, B, C are hybridized to form a pincer shape; switching is effected by means of a further auxiliary DNA strand, in which one oligonucleotide strand F is hybridized to the free end of strand B, C, the pincer-like molecule is closed, and subsequently, the complementary strand of F is passed
Opening the pincer-like molecules to circulate, thereby achieving the effect of cruising motion;
the monitoring component is used for monitoring various biochemical indexes in the blood and transmitting signals to the sensing component;
the sensing component is used for transmitting the biochemical parameters collected by the monitoring component to the AR equipment and is a bridge connecting the nano-biological monitor and the AR equipment;
the framework part is used as a supporting part, wherein the monitoring part is embedded on the surface of the framework part, the sensing part is positioned at the center of the framework part, and the cruising part is connected on the surface of the framework part;
the monitoring component is used for monitoring probe regions of serum alpha-fetoprotein (AFP), cancer antigen 242(CA242), cancer antigen 125(CA125), cancer antigen 153(CA153) and cancer antigen 724(CA 724); wherein, the serum alpha-fetoprotein (AFP) is helpful for the diagnosis of primary liver cancer; cancer antigen 242(CA242) is a tumor antigen specific for pancreatic and gallbladder cancer; cancer antigen 125(CA125) is an antigen associated with ovarian cancer; cancer antigen 153(CA153) is the first marker for breast cancer; cancer antigen 724(CA724) is one of the best tumor markers for gastric cancer.
2. The nanobiomonitor according to claim 1, wherein the sensing member is a wireless sensing chip; the device not only has the function of transmitting signals, but also can sense and receive the electric signals of the monitoring component; the system comprises an acquisition unit and a communication unit; the acquisition unit is used for sensing, acquiring and receiving signals transmitted by the probes in the monitoring component as claimed in claim 1, and summarizing the parameters through the communication unit and transmitting the parameters to the AR equipment through wifi.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010550977.6A CN111665350A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711135596.6A CN107942070B (en) | 2017-11-16 | 2017-11-16 | A nanobiomonitor for blood cruise and its emergency information AR display |
| CN202010550977.6A CN111665350A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711135596.6A Division CN107942070B (en) | 2017-11-16 | 2017-11-16 | A nanobiomonitor for blood cruise and its emergency information AR display |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111665350A true CN111665350A (en) | 2020-09-15 |
Family
ID=61931426
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711135596.6A Active CN107942070B (en) | 2017-11-16 | 2017-11-16 | A nanobiomonitor for blood cruise and its emergency information AR display |
| CN202010550964.9A Withdrawn CN111665349A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
| CN202010550400.5A Withdrawn CN111665348A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
| CN202010550977.6A Withdrawn CN111665350A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711135596.6A Active CN107942070B (en) | 2017-11-16 | 2017-11-16 | A nanobiomonitor for blood cruise and its emergency information AR display |
| CN202010550964.9A Withdrawn CN111665349A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
| CN202010550400.5A Withdrawn CN111665348A (en) | 2017-11-16 | 2017-11-16 | Nanometer biological monitor for blood cruising |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN107942070B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112075942A (en) * | 2020-07-03 | 2020-12-15 | 黑龙江仁芯众康生物科技有限公司 | Nanometer biological detector for noninvasive evaluation of stability of arteriosclerotic plaque |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744645B (en) * | 2008-12-17 | 2012-09-05 | 中国科学院生物物理研究所 | Nanometer biological robot and application thereof |
| US10359395B2 (en) * | 2014-02-19 | 2019-07-23 | University Of Washington | Nanopore-based analysis of protein characteristics |
-
2017
- 2017-11-16 CN CN201711135596.6A patent/CN107942070B/en active Active
- 2017-11-16 CN CN202010550964.9A patent/CN111665349A/en not_active Withdrawn
- 2017-11-16 CN CN202010550400.5A patent/CN111665348A/en not_active Withdrawn
- 2017-11-16 CN CN202010550977.6A patent/CN111665350A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107942070B (en) | 2020-12-01 |
| CN107942070A (en) | 2018-04-20 |
| CN111665349A (en) | 2020-09-15 |
| CN111665348A (en) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adhit et al. | Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine | |
| Singh et al. | Tailored point-of-care biosensors for liquid biopsy in the field of oncology | |
| Nayak et al. | Point-of-care diagnostics: recent developments in a connected age | |
| Xu et al. | Advances in smartphone-based point-of-care diagnostics | |
| Le et al. | Array-based sensing using nanoparticles: an alternative approach for cancer diagnostics | |
| Lopez-Barbosa et al. | The future point-of-care detection of disease and its data capture and handling | |
| EP2895852A1 (en) | Apparatus and method for point-of-collection measurement of a biomolecular reaction | |
| US20220389511A1 (en) | Systems and methods for artifical intelligence based cell analysis | |
| Sun et al. | Accurate diagnosis of thyroid cancer using a combination of surface-enhanced Raman spectroscopy of exosome on MXene-coated gold@ silver core@ shell nanoparticle substrate and deep learning | |
| US10935495B2 (en) | Detection and analysis method for urine-modified nucleoside based on surface-enhanced resonance Raman spectroscopy | |
| WO2016064917A1 (en) | Systems and methods for personalized sample analysis | |
| WO2021099677A1 (en) | Device and method for detecting of brain injury in a subject | |
| Chi et al. | Fast and sensitive detection of protein markers using an all-printing photonic crystal microarray via fingertip blood | |
| Ghazi et al. | A review of aptamer-based surface-enhanced Raman scattering (SERS) platforms for cancer diagnosis applications | |
| Younis et al. | Smartphone‐Based Biosensors | |
| CN114813701B (en) | A SERS biosensor and its preparation method and application | |
| Bhatti et al. | Advances in sensor technologies for breast cancer detection: a comprehensive review of imaging and non-imaging approaches | |
| CN111665350A (en) | Nanometer biological monitor for blood cruising | |
| Ou et al. | Liquid Biopsy on Microfluidics: From Existing Endogenous to Emerging Exogenous Biomarkers Analysis | |
| CN103512972A (en) | Biomarkers for schizophrenia and methods and applications for their use | |
| Moghimikandelousi et al. | Advances in biomonitoring technologies for women’s health | |
| Kelley | Disease detector | |
| Kight | Advancements in point-of-care diagnostic assays for non-invasive samples in resource constrained settings | |
| Lopes et al. | Advances towards gastric cancer screening: Novel devices and biomarkers | |
| Mathur et al. | A review on breast cancer diagnostic techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200915 |